default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Sillajen reports 1st patient enrollment for Pexa-Vec’s Chinese P3 trials

Lee Han-soo  Published 2018.09.03  17:59  Updated 2018.09.03 17:59

공유
default_news_ad2

Sillajen announced Monday that the company has enrolled its first patient for a phase 3 clinical trial for Pexa-Vec in treating people with liver cancer in China

The company plans to register patients who have not taken Nexavar and have a certain level of immunity. Such recruitment requirement is because a patient needs at least some immunity level for the immunotherapeutic drugs to be effective, the company said.

“As a doctor who treats many patients with liver cancer, I understand the unmet needs of patients with liver cancer in Asia and around the world,” said Professor Shukui Qin, the lead researcher for the phase 3 clinical trial in China.

The hospital expects that Pexa-Vec will become a potential treatment for patients, he added.

About 500,000 people out of 900,000 liver cancer patients worldwide are known to be living in China. To receive sales approval in the country, a company has to complete a clinical trial on Chinese patients.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch